|
1
|
Teta MJ, Mink PJ, Lau E, Sceurman BK and
Foster ED: US mesothelioma patterns 1973–2002: Indicators of change
and insights into background rates. Eur J Cancer Prev. 17:525–534.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krug LM, Pass HI, Rusch VW, Kindler HL,
Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K,
Monberg M, et al: Multicenter phase II trial of neoadjuvant
pemetrexed plus cisplatin followed by extrapleural pneumonectomy
and radiation for malignant pleural mesothelioma. J Clin Oncol.
27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edwards JG, Abrams KR, Leverment JN, Spyt
TJ, Waller DA and O'Byrne KJ: Prognostic factors for malignant
mesothelioma in 142 patients: Validation of CALGB and EORTC
prognostic scoring systems. Thorax. 55:731–735. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Opitz I: Management of malignant pleural
mesothelioma - the European experience. J Thorac Dis. 6:(Suppl 2).
S238–S252. 2014.PubMed/NCBI
|
|
5
|
Baldini EH: Radiation therapy options for
malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg.
21:159–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Meerbeeck JP, Gaafar R, Manegold C,
Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A,
Debruyne C and Giaccone G: European Organisation for Research and
Treatment of Cancer Lung Cancer Group; National Cancer Institute of
Canada: Randomized phase III study of cisplatin with or without
raltitrexed in patients with malignant pleural mesothelioma: An
intergroup study of the European Organisation for Research and
Treatment of Cancer Lung Cancer Group and the National Cancer
Institute of Canada. J Clin Oncol. 23:6881–6889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stebbing J, Powles T, McPherson K, Shamash
J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D and Steele JP:
The efficacy and safety of weekly vinorelbine in relapsed malignant
pleural mesothelioma. Lung Cancer. 63:94–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Meerbeeck JP, Baas P, Debruyne C,
Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz
M and Giaccone G: European Organization for Research and Treatment
of Cancer Lung Cancer Cooperative Group: A phase II study of
gemcitabine in patients with malignant pleural mesothelioma.
European organization for research and treatment of cancer lung
cancer cooperative group. Cancer. 85:2577–2582. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brunner TB and Scott-Brown M: The role of
radiotherapy in multimodal treatment of pancreatic carcinoma.
Radiat Oncol. 5:642010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ghosn M, Kourie HR, El Karak F, Hanna C,
Antoun J and Nasr D: Optimum chemotherapy in the management of
metastatic pancreatic cancer. World J Gastroenterol. 20:2352–2357.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
National Cancer Institute of Canada Clinical Trials Group:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Belli C, Cereda S and Reni M: Role of
taxanes in pancreatic cancer. World J Gastroenterol. 18:4457–4465.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saif MW: U.S. Food and Drug Administration
approves paclitaxel protein-bound particles (Abraxane®)
in combination with gemcitabine as first-line treatment of patients
with metastatic pancreatic cancer. JOP. 14:686–688. 2013.PubMed/NCBI
|
|
17
|
Kothari N, Saif MW and Kim R: First-line
treatment for advanced pancreatic cancer. JOP. 14:129–132.
2013.PubMed/NCBI
|
|
18
|
Attanoos RL, Thomas DH and Gibbs AR:
Synchronous diffuse malignant mesothelioma and carcinomas in
asbestos-exposed individuals. Histopathology. 43:387–392. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bianchi C, Bianchi T and Ramani L:
Malignant mesothelioma of the pleura and other malignancies in the
same patient. Tumori. 93:19–22. 2007.PubMed/NCBI
|
|
20
|
Curran D, Sahmoud T, Therasse P, van
Meerbeeck J, Postmus PE and Giaccone G: Prognostic factors in
patients with pleural mesothelioma: The European Organization for
Research and Treatment of Cancer experience. J Clin Oncol.
16:145–152. 1998.PubMed/NCBI
|
|
21
|
Raucci R, Colonna G, Guerriero E, Capone
F, Accardo M, Castello G and Costantini S: Structural and
functional studies of the human selenium binding protein-1 and its
involvement in hepatocellular carcinoma. Biochim Biophys Acta.
1814:513–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Robinson BW, Musk AW and Lake RA:
Malignant mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang W, Wu X, Wu L, Zhang W and Zhao X:
Advances in the diagnosis, treatment and prognosis of malignant
pleural mesothelioma. Ann Transl Med. 3:1822015.PubMed/NCBI
|
|
25
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Agaimy A and Wünsch PH: Epithelioid and
sarcomatoid malignant pleural mesothelioma in endoscopic gastric
biopsies: A diagnostic pitfall. Pathol Res Pract. 202:617–622.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen HC, Tsai KB, Wang CS, Hsieh TJ and
Hsu JS: Duodenal metastasis of malignant pleural mesothelioma. J
Formos Med Assoc. 107:961–964. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang YJ, Wu MH and Lin MT: Multiple
small-bowel intussusceptions caused by metastatic malignant
melanoma. Am J Surg. 196:e1–e2. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eo WK, Kim GY and Choi SI: A case of
multiple intussusceptions in the small intestine caused by
metastatic renal cell carcinoma. Cancer Res Treat. 40:97–99. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Terashita S, Hirano K, Hirai T,
Narabayashi T, Hara Y, Mori H, Endo K and Hirabayashi M: A case of
malignant pleural mesothelioma with gastrointestinal metastases
which were diagnosed by endoscopic biopsy. Nihon Kokyuki Gakkai
Zasshi. 47:133–138. 2009.(In Japanese). PubMed/NCBI
|
|
31
|
Gocho K, Isobe K, Kaburaki K, Honda Y,
Mitsuda A, Akasaka Y, Shimada N, Takagi K and Homma S: Malignant
pleural mesothelioma presenting as an acute surgical abdomen due to
metastatic jejunal perforation. Intern Med. 49:597–601. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu H, Cheng YJ, Chen HP, Hwang JC and
Chang PC: Multiple bowel intussusceptions from metastatic localized
malignant pleural mesothelioma: A case report. World J
Gastroenterol. 16:3984–3986. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martínez Caselles A, Baños Madrid R, Egea
Valenzuela J, Molina Martínez J and Carballo Álvarez F:
Gastrointestinal bleeding secondary to duodenal metastases of
malignant pleural mesothelioma. Rev Esp Enferm Dig. 102:602–603.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Vin T, Engels B, Gevaert T, Storme G
and De Ridder M: Stereotactic radiotherapy for oligometastatic
cancer: A prognostic model for survival. Ann Oncol. 25:467–471.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alongi F, Arcangeli S, Filippi AR, Ricardi
U and Scorsetti M: Review and uses of stereotactic body radiation
therapy for oligometastases. Oncologist. 17:1100–1107. 2012.
View Article : Google Scholar : PubMed/NCBI
|
